UGOT

2 mars 2023

Distinct biological profiles associated with the risk of short-term relapse and mid/long-term relapse in Crohn’s disease patients stopping infliximab.

10 janvier 2023

ECCO Topical Review on Biological Treatment Cycles in Crohn’s Disease.

3 octobre 2022

A serum metabolite panel predicts Crohn’s disease relapse in patients discontinuing infliximab and continuing antimetabolite therapy: sub-analysis of the SPARE Trial.